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Abstract
Iron–sulfur (Fe–S) clusters are essential cofactors for proteins that participate in fundamental
cellular processes including metabolism, DNA replication and repair, transcriptional regulation,
and the mitochondrial electron transport chain (ETC). ISCA2 plays a role in the biogenesis of
Fe–S clusters and a recent report described subjects displaying infantile-onset leukodystrophy
due to bi-allelicmutation of ISCA2.Wepresent two additional unrelated cases, and provide amore
complete clinical description that includes hyperglycinemia, leukodystrophyof the brainstemwith
longitudinally extensive spinal cord involvement, and mtDNA deficiency. Additionally, we charac-
terize the role of ISCA2 in mitochondrial bioenergetics and Fe–S cluster assembly using subject
cells and ISCA2 cellular knockdown models. Loss of ISCA2 diminished mitochondrial membrane
potential, themitochondrial network, basal andmaximal respiration, ATP production, and activity
of ETC complexes II and IV.We specifically tested the impact of loss of ISCA2 on 2Fe–2S proteins
versus 4Fe–4S proteins and observed deficits in the functioning of 4Fe–4S but not 2Fe–2S pro-
teins. Together these data indicate loss of ISCA2 impaired function of 4Fe–4S proteins resulting
in a fatal encephalopathy accompanied by a relatively unusual combination of features including
mtDNAdepletion alongside complex II deficiency and hyperglycinemia thatmay facilitate diagno-
sis of ISCA2 deficiency patients.
K EYWORDS
encephalopathy, Fe-S clusters, hyperglycinemia, ISCA2, leukodystrophy, mitochondrial dysfunc-
tion
1 INTRODUCTION
Iron–sulfur (Fe–S) clusters are sulfide-linked iron molecules that
serve as an essential cofactor for iron–sulfur proteins, which func-
tion throughout the cell to perform several fundamental cellular pro-
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
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cesses including transcriptional regulation, DNA and RNA synthesis
and repair, electron transport, iron and heme metabolism, and oxygen
sensing (Rouault, 2015; Stehling, Wilbrecht, & Lill, 2014). The genera-
tion of Fe–S clusters is an evolutionarily conserved multistep process
involving over 15 proteins. However, the complete elucidation of the
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mechanismandmachinery responsible for their biogenesiswithin each
organism remains unresolved.
In humans, Fe–S cluster biogenesis is largely restricted to mito-
chondria for most Fe–S proteins including those that function in the
mitochondria, cytosol, and nucleus (Lill et al., 2015; Rouault, 2015).
There is evidence to suggest Fe–S biosynthesis may also occur
independently in the cytosol and nuclear compartments, commonly
referred to as the cytosolic Fe–S protein assembly (CIA) machin-
ery that includes complexes for electron transfer, scaffolding, target-
ing and adapter function (Biederbick et al., 2006; Lill et al., 2015;
Rouault, 2012, 2015; Tong & Rouault, 2006). The mitochondrial mul-
tiprotein Fe–S cluster (ISC) assembly machinery is responsible for de
novo synthesis of clusters and assembles 2Fe–2S clusters onto scaf-
folding protein ISCU (Maio & Rouault, 2015; Stehling et al., 2014).
Clusters may then be exported into the cytosol for further process-
ing and integration into recipient iron sulfur proteins that ultimately
function in the cytosol or nucleus or are retained within the mito-
chondria. 4Fe–4S clusters are formed from mature 2Fe–2S clusters
within the mitochondria and molecular evidence has implicated a role
for ISCA1 (MIM# 611006), ISCA2 (MIM# 615317), and IBA57 (MIM#
615316) in this process (Muhlenhoff, Richter, Pines, Pierik, & Lill, 2011;
Sheftel et al., 2012; Stehling et al., 2014). Characterization of these
genes in Saccharomyces cerevisiae showed yeast orthologs ISA1, ISA2,
and IBA57 were essential for proper maturation of 4Fe–4S proteins
(Gelling, Dawes, Richhardt, Lill, & Muhlenhoff, 2008; Melber et al.,
2016; Muhlenhoff et al., 2011). Knockdown of either ISCA1 or ISCA2
in HeLa cells showed diminished activity of mitochondrial aconitase,
complex I, and succinate dehydrogenase; the proper functioning of
which rely on 4Fe–4S clusters (Sheftel et al., 2012). In contrast, HeLa
cells depletedof ISCA1or ISCA2 showed these geneswerenot required
for ferrochelatase activity, which is a 2Fe–2S cluster protein. Struc-
tural characterization of ISCA1 and ISCA2 in vitro showed that an
ISCA2 homodimer binds either 2Fe–2S or 4Fe–4S cluster and the
ISCA1–ISCA2 heterodimer can bind two 2Fe–2S or 4Fe–4S clusters
(Brancaccio et al., 2014).
A recent study described five independent consanguineous Ara-
bic families with six affected children homozygous for a pathogenic
missense variant in exon 3 of ISCA2 (NM_194279.2 c.229G>A;
p.Gly77Ser) (Al-Hassnan et al., 2015). Phenotypic hallmarks included
infantile-onset developmental regression to a vegetative state, spas-
tic tone, and optic atrophy. Characteristic cranial MRI findings did not
include structural abnormalities, but rather extensive signal abnormal-
ities in cerebral white matter and other regions including the cerebel-
lum, middle cerebellar peduncles, and corpus callosum. Patient fibrob-
lasts showed reduced copy number of mitochondrial DNA (mtDNA)
and complex I enzyme activity at 20% of control, whereas other com-
ponents of the electron transport chain (ETC) were not tested (Al-
Hassnan et al., 2015). Two unrelated patients with different novel
homozygous missense variants in ISCA2 (NM_194279.2 c.154C>T;
p.Leu52Phe and c.313A>G; p.Arg105Gly) have been described, but
with limited clinical information (Lebigot et al., 2017). Both patients’
fibroblasts showed a reduction of complex I activity and elevated com-
plex III activity. Further analyses of these twopatients showed conflict-
ing results.
Here, we report the clinical description and functional character-
ization of two new, unrelated affected subjects who, like previously
reported patients, are homozygous for the pathogenic ISCA2missense
variant c.229G>A; p.Gly77Ser. We identified a profile of metabolic
dysfunction that includes elevated CSF glycine and glutamate
alongside low 5-methyltetrahydrofolate. We provide a full functional
characterization of mitochondrial bioenergetics, oxidative phospho-
rylation, and maintenance of the mitochondrial genome in tissue from
patients harboring this founder mutation. Additionally, using both
patient tissues and a human cell-based ISCA2 depletion model, we
provide further support for the role of ISCA2 in the production of
4Fe–4S cluster proteins.
2 MATERIALS AND METHODS
2.1 Subjects
Informed consent for research studies was obtained in accordance
withprotocols approvedby local Institutional ReviewBoards.Genomic
DNA was extracted from peripheral-blood lymphocytes according to
standard protocols.
2.2 Genetic analyses
Whole exome sequencing of Subject 1 was undertaken as part of a
research study at Baylor College of Medicine, whereas Subject 2 had
clinical diagnostic exome sequencing at Baylor Genetics Laboratories
at Baylor College of Medicine. Exome capture sequencing was con-
ducted using Illumina paired-end pre-capture library with the HGSC
CORE exome capture design (52 Mb; NimbleGen) and subsequently
sequenced on a HiSeq 2500 to an average 20× or greater coverage.
Bioinformatic analyses were conducted as previously reported (Stiles
et al., 2015). SNVs and small insertions and deletions (InDels) were
scored byGATK (DePristo et al., 2011).Quality control filtering of vari-
ants was based on coverage, strand bias, mapping quality, and base
quality. Custom Perl scripts were used to annotate variants as previ-
ously described (Bonnenet al., 2013). Algorithmsused for predictionof
potential functional consequences of variants includedCADD (Kircher
et al., 2014), SIFT (Ng & Henikoff, 2002), PolyPhen2 (Adzhubei et al.,
2010), Genomic Evolutionary Rate Profiling (GERP) (Davydov et al.,
2010), and PhyloP (Cooper et al., 2005).
The candidate ISCA2 variant identified through exome sequencing
was orthogonally validated and recessive segregation through the sub-
jects’ pedigrees was confirmed using PCR-based Sanger sequencing.
All genetic alleles studied were annotated in reference to ISCA2
NM_194279.2 for cDNA and NP_919255 for protein. The ISCA2
NM_194279.2 c.229G>A; p.Gly77Ser variant has ClinVar Variation ID
190396 https://www.ncbi.nlm.nih.gov/clinvar/variation/190396/.
2.3 Primary fibroblast and glioblastoma cell culture
Fibroblasts were grown in DMEM High Glucose (Hyclone) supple-
mented with 15% FBS. Glioblastoma cells T98G were obtained from
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the American Type Culture Collection (Manassas, VA) and grown in
complete Eagle's minimum essential medium (ATCC) supplemented
with 10% FBS. For nucleoside rescue experiments, fibroblasts were
grown in DMEM supplemented with 1% FBS (low serum medium,
LSM), in absence or presence of 150 𝜇M dNTP mix, for 10 days. LSM
was replaced with fresh medium with or without dNTPs every 2 days.
After 10 days, cells were harvested.
2.4 Assessment ofmitochondrial membrane
potential
Mitochondrial membrane potential was assessed as previously
described (Bonnen et al., 2013). Briefly, cells were grown to conflu-
ence, counted and stained directlywithDilC1(5) or pre-incubatedwith
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) prior to staining
(MitoProbe DilC1(5) Assay kit for Flow Cytometry; Life Technologies).
Results are reported as the difference between themean fluorescence
intensity of cells that received treatment with CCCP versus those
that did not. Assays were conducted in triplicate and are shown as the
average and standard deviation.
2.5 Immunoblotting
Immunoblotting for components of the ETC was conducted on crude
mitochondrial extracts prepared from fibroblasts grown under nor-
mal conditions. Cell pellets were re-suspended in ice-cold isolation
buffer (20 mM HEPES pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 250 mM sucrose) and allowed to swell for 20 min
on ice. The cell suspension was briefly homogenized and then cen-
trifuged for 5 min at 1,000g at 4◦C. Mitochondria were sedimented
from the supernatant by centrifugation at 10,000g for 15 min at 4◦C.
Themitochondria pelletwaswashedoncewith ice-cold isolationbuffer
and then resuspended in RIPA buffer containing 50 mM Tris, pH 8.0,
150mMNaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS,
5 mg/ml leupeptin, 2 mg/ml aprotinin, and 0.5 mM PMSF. The samples
were incubated on ice for 15 min and the lysates were centrifuged at
20,000g for 30 min at 4◦C. Ten micrograms of mitochondrial lysates
was resolved by SDS-PAGE and transferred to a 0.45 mm PVDFmem-
brane (Millipore). The membrane was immunoblotted using antibod-
ies specific for subunits of the human mitochondrial OXPHOS com-
plexes: NDUFB8, SDHA,UQCRC2, andCOX1 (Abcam). Themembrane
was next incubated in stripping buffer (62.5 mM Tris, pH 6.8, 2% SDS,
100mM2-mercaptoethanol) for 15min at 50◦C, and then probedwith
TOMM20 (Abcam) as mitochondrial protein loading control. ImageJ
software was used to perform the relative quantification of the bands
with TOMM20 used for normalization.
Immunoblotting for ABAT (Abcam), ISCA2 (Invitrogen), porin
(Abcam), and Lipoic Acid (Calbiochem) was conducted in patient
fibroblasts and in T98G glioblastoma cells expressing shRNA target-
ing ABAT and ISCA2, as well as a non-target shRNA control. Twenty
micrograms of whole cell extract, prepared by standard methods, was
resolved on SDS-PAGE and transferred to a 0.45mmPVDFmembrane
(Millipore). ImageJ software was used to perform the relative quantifi-
cation of the bands with actin used for normalization.
2.6 Microscale oxygraphy
Fibroblasts were cultured for 10 days in DMEM containing 25 mM
galactose and supplemented with 15% FBS. XF24 extracellular flux
analyzer from Seahorse Biosciences was used to measure the rates
of oxygen consumption. Cells were plated the previous day of experi-
ment on the XF24 cell culture microplates (Seahorse Biosciences) at a
density of 30,000 cells perwell. XF24 cartridge (Seahorse Biosciences)
was equilibrated with the calibration solution (Seahorse Biosciences)
overnight at 37◦C. XF assay medium (5 mM galactose, 2 mM Pyru-
vate) in XF base media (Seahorse Biosciences) was prepared and pH
adjusted to 7.0 on the day of the experiment. Oxygen consumption
rates (OCRs) were measure for 3 min with 3 min of mixing and 2 min
waiting period after each injection of individual cellular stress reagents
in the order listed here: 500 nM Oligomycin, 500 nM FCCP, 100 nM
Antimycin, and 100 nMRotenone (Sigma–Aldrich). After the assaywas
completed, cells in each well were counted using ViCell cell viability
analyzer (BeckmanCoulter) and the countswere used to normalize the
OCRs.
2.7 Mitochondrial morphology
Fibroblasts were seeded on micro-Slide VI flat for Live Cell Analysis
(Ibidi). Cells were incubated with 3 𝜇l/ml PicoGreen (Life Technolo-
gies) for 60 min then incubated with 50 nMMitoTracker Red CMXRos
for 10 min. Next, the staining solution was replaced with fresh growth
medium and the cells incubated 20 min. Cells were visualized at 60×
magnification using a Nikon Eclipse 90i microscope equipped with
TRITC and FITC filters. The images were processed with NIS-elements
v3.0 software.
2.8 Quantitation ofmtDNA copy number
Mitochondrial genome copy number was determined by real-time
quantitative PCR as previously described with minor modification
(Bonnen et al., 2013). Briefly, the mitochondrial genome copy num-
ber was determined relative to the nuclear genome using a region of
MTND1 to represent themitochondrial genome and B2M representing
the nuclear genome. The assay utilized StepOne Plus RT-PCR system
(AppliedBiosystems) andPerfeCTa SYBRGreen FastMix ROX (Quanta
Biosciences). The assay was performed in triplicate. mtDNA content
(mtDNA/B2M ratio) was calculated using the formula: mtDNA con-
tent= 1/2ΔCt, whereΔCt=CtmtDNA−CtB2M.
2.9 shRNA knockdown of ABAT and ISCA2
To knockdown ABAT and ISCA2 expression, T98G glioblastoma cells
were transfectedwith specific targeting shRNA (ABAT:Mission shRNA
TRCN0000034927, ISCA2: Mission shRNA Sigma–Aldrich) and a
non-target shRNA control (SHC016; Sigma–Aldrich) using Lipofec-
tamine 2000 (Life Technologies). Forty-eight hours after transfection,
puromycinwas added to the culturemedium to select transfected cells.
After 7 days selection, the cells were allowed to recover and grown in
normal media for 3 more days. Cells were harvested and total DNA,
RNA, and protein were isolated using standard techniques.
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2.10 Quantitation ofmRNA
RNA extraction from T98G cells expressing non-targeting con-
trol shRNA, ABAT shRNA, and ISCA2 shRNAs was performed
using TRIzol reagent (Life Technologies) according to manufacturer's
instructions. After extraction, the RNA was treated with RQ1 RNase-
free DNase for 40 min at 37◦C. The RNA was then purified using
PureLink RNAmini kit (Life Technologies). After resuspension in Ultra-
Pure Distilled water (Life Technologies), the RNAwas quantified using
Quant-iTRiboGreenRNAassay kit (Life Technologies).Onemicrogram
of RNA was used as template for first-strand cDNA synthesis using
SuperScript III First-Strand Synthesis System for RT-PCR (Life Tech-
nologies) andoligo-dT according tomanufacturer's instructions.Quan-
titative real-time PCR experiments were performed using a StepOne
Plus RT-PCR system (Applied Biosystems). RT2 qPCR Primer Assays
for Human GAPDH and ABAT were purchased from SABiosciences.
Oligonucleotides for ISCA2werepurchased fromSigma–Aldrich (F: 5′-
tcacagacagttgcgtcca-3′ and R: 5′-gtcgtcggggttgataactg-3′). PerfeCTa
SYBR Green FastMix ROX was purchased from Quanta Biosciences.
One microliter of cDNA template was used per reaction (20 𝜇l). Each
sample was run in triplicate. The cycling conditions were as follow:
95◦C for 3 min (95◦C, 15 sec–60◦C, 1 min) repeated for 35 cycles. The
absence of primer dimers and non-specific amplification products was
confirmedby performingmelting curve analysis. The cycle of threshold
value (Ct) was normalized to the transcripts for the housekeeping gene
GAPDH.
2.11 ETC enzymatic activity
Total protein was harvested from cells by standard methods. Briefly,
cells were washed in PBS and trypsinized for 3 min at 37◦C.
Washed two more times in PBS and pellet collected each time.
Pellets were sonicated in sonication medium (100 mM Tris, 2 mM
EDTA, 250 mM sucrose, pH 7.4) for 5 sec at 60% power on a
Misonix Microson XL200 Ultrasonic Cell Disruptor. Protein con-
centration was determined using Pierce BCA protein assay kit
and samples adjusted to 1 mg/𝜇l to perform spectrophotometric
kinetic assays. Absorbances were read on a Synergy II microplate
reader (Biotek). Enzymatic activity of complexes I–IV and CS were
measured as previously published (Kirby, Thorburn, Turnbull, &
Taylor, 2007). Complex I activity was determined by measuring
rotenone sensitive NADH oxidation (340 nm), complex II activity by
measuring DCIP reduction (600 nm), complex III activity by measur-
ing cytochrome c reduction (550 nm), complex IV activity by measur-
ing oxidation of reduced cytochrome c. Citrate synthase activity by
measuring the color of TNB (412 nm), which is generated from DTNB
present in the reaction of citrate synthesis, and caused by the deacety-
lation of Acetyl-CoA. Activities were calculated as nmol/min/mg pro-
tein. All assays were conducted in triplicate and expressed as percent-
age of control.
2.12 GABA transaminase enzymatic activity
T98G cells expressing non-targeting control shRNA, ABAT shRNA, and
ISCA2 shRNAs were harvested and GABA-T enzymatic activity was
determined using a GABA-T assay kit (Biomedical Research Service
Center, Buffalo University, NY) according to manufacturer instruc-
tions. Briefly, the assay is based on sequential GABA-T transami-
nation reaction and glutamate dehydrogenase reaction, which cou-
ples the reduction of iodonitrotetrazolium to iodonitrotetrazolium-
formazan (Ɛ = 18 mM−1 cm−1 at 492 nm). Each sample (10 𝜇g) was
assayed in duplicate in a 96-well plate: one set for control wells
(no substrate) and one set for reactions wells (containing GABA-T
substrate). After the incubation periods, the reactions were termi-
nated by adding 3% acetic acid (Sigma–Aldrich, St. Louis, MO). The
OD at 492 nm was measured using a plate reader (Phenix Sun-
rise series; Tecan). Readings were averaged and control wells read-
ings were subtracted from sample wells readings (ΔOD). GABA-T
activity was calculated using the following formula: GABA-T activity
(𝜇mol/(l min)= (ΔOD× 1,000× 155 𝜇l)/(60min× 0.6 cm× Ɛ× 10 𝜇l)=
ΔOD × 23.92, where 155 𝜇l is the total reaction volume, 0.6 cm the
light path in the 96-well plate, 10 𝜇l the volume of sample in each well.
The results were graphed as percentage of control.
3 RESULTS
3.1 Clinical description
Subject 1 is a male of Saudi Arabian origin with a family history sig-
nificant for consanguinity and maternal family history positive for
leukodystrophy (Figure 1A). The subject's early development was nor-
mal until 3 months of age when he had nystagmus and stiff legs. He
never sat and at 6 months, there was motor regression with loss of
social interaction. Examination at 1 year and 2 months of age revealed
signs of central hypotonia with four limb spasticity but normal head
circumference. There was optic atrophy with no visual interaction and
absent visual evokedpotentials. Bulbar dysfunctionwas significant and
nasogastric feeding was required. Brain MRI revealed high T2 signal
abnormalities in the white matter including subcortical U fibers and
periventricular white matter, extending into the posterior limbs of the
internal capsule, posterior body and splenium of the corpus callosum
andcerebral peduncles. Abnormal signalwas alsodemonstratedwithin
the dorsal tegmental tracts, inferior cerebellar peduncles and cerebel-
lar white matter. There was restricted diffusion within the dorsal pon-
tine tracts and inferior cerebellar peduncles and abnormal T2 signal
change from the craniocervical junction to T11 cord. Brain magnetic
resonance spectrometry (MRS) identified an elevated lactate peak.
This combination of leukodystrophy of brainstem and spinal cord with
elevated lactate is very similar to findings in subjects with recessively
inherited DARS2 mutations though subtle differences in the precise
pattern of signal abnormalities in the brainstem and spinal cord may
distinguish these two genetic etiologies (Steenweg et al., 2011).
Biochemical testing of cerebrospinal fluid (CSF) revealed elevated
glycine (43.0 𝜇mol/l; range: 1.9–10) elevated glutamate (18 𝜇mol/l;
range: 0–3.9) and low 5-methyltetrahydrofolate (46 nmol/l; range:
72–305). Glycine and glutamate levels in plasma were normal; like-
wise for other plasma amino acid levels. Urine values of glycine
and glutamate were elevated (glycine = 2,393 𝜇mol/l; range: 92–
760) (glutamate = 54 𝜇mol/l; range: 0–32). While CSF lactate was
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F IGURE 1 Pedigrees and cranial MRI for ISCA2 deficiency subjects. A: Pedigree of Subject 1 revealed maternal family history for fatal infantile
leukodystrophy (filled symbols indicate affected individual). MRI of Subject 1 identified high T2 signal abnormalities in white matter indicating
leukodystrophy which also spanned the entire length of the spinal cord (1–4). B: Subject 2 family history was positive for consanguinity and a
history of early infantile leukodystrophy fatality (filled symbols indicate affected individual). Axial T2-weighted images and Axial T1 images of
proband show hyperintensities in the central and periventricular white matter (1–3)
elevated (lactate = 6.69 𝜇mol/l; range 1.1–2.2), plasma values were
normal (lactate 1.84 𝜇mol/l; range 0.7–2.1). Additional metabolic find-
ings includedelevatedplasmachitotriosidase activity (500nmol/hr/ml;
range: 0–150), decreased palmitoyl protein thioesterase activity
(12 nmol/hr/mg ptn; range: 17–139), decreased 𝛽-galactosidase activ-
ity (143 nmol/hr/mg ptn; range 163–378), and decreased arylsulfatase
Aactivity (17nmol/hr/mgptn; range: 22–103).At timeof reporting, the
subject was still alive, and was most recently reviewed clinically at age
3 years 5months (Table 1).
Subject 2 is a female of Saudi Arabian origin who presented to clinic
at age 6months with diffuse hypotonia and developmental regression.
Family history was significant for parental first-cousin consanguinity,
twomiscarriages and five siblings who died in infancy from demyelina-
tion and white matter disease associated with regression (Figure 1B).
Her development was normal until about 6 months of age when she
stopped making sounds, diminished eye contact, lost the ability to roll
and became unable to move. Further evaluations at 9 months of age
revealed spasticity, optic nerve pallor and visual impairment. Brain
MRI at this time showed leukodystrophy with diffuse T1 and T2 signal
abnormalities in the white matter, in the frontoparietal, occipital, and
both cerebellar hemispheres (Figure 1B). Brain MRS identified a large
lactate peak. Additional features included poor growth with relative
macrocephaly, and skeletal abnormalities including joint laxity, short
fourth metacarpals and cutaneous toe syndactyly. Skeletal abnormal-
ities have not been reported in the previous ISCA2 deficiency subjects.
Subject 2 died aged 9months. Nometabolic testing was conducted.
3.2 Genetic analyses
Exome sequencing was conducted on Subject 1 and Subject 2 and both
individualswere found tobehomozygous for ISCA2variant, c.229G>A;
p.Gly77Ser, that was recently reported pathogenic in a group of six
individuals from five independent consanguineous families with sim-
ilar clinical presentation (Al-Hassnan et al., 2015). Sequencing of the
parents of each proband showed all were heterozygous for the ISCA2
variant and confirmed recessive inheritance in the families.
3.3 ISCA2mutation results in deficiency of
mitochondrial bioenergetics
Mitochondrial membrane potential is the electrical gradient across the
inner mitochondrial membrane generated by the reductive transfer
of electrons through the ETC protein complexes. This reflects cellular
capacity to generate ATP by oxidative phosphorylation and as such,
is an indicator of mitochondrial and cellular health. The membrane
potential of dermal fibroblasts from Subject 1 was significantly dimin-
ished relative to control (P < 0.001) indicating mitochondrial dysfunc-
tion (Figure 2A).
We next directly assessed the biochemical activity of each of ETC
complexes I, II, III, and IV plus citrate synthase in fibroblasts from Sub-
ject 1. The activity of complexes I and III were marginally increased,
whereas complexes II and IV were markedly decreased to 60% and
70%of control respectively (Figure 2B). Citrate synthasewas the same
as control fibroblasts. While the decreases in activity of complexes II
and IV were significant, neither was sufficient to meet the Modified
Walker diagnostic criteria. An additional assessment of capacity for
oxidative phosphorylation in fibroblasts from Subject 1was conducted
by immunoblotting for specific components of each complex of the
ETC. Similar to biochemical activity, this revealed an increase in Com-
plex I subunitNDUFB8and a significant decrease inComplex II subunit
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TABLE 1 Summary of patient clinical features
Subject 1 Subject 2
ISCA2 variant
(NM_194279.2)
c.229G>A
p.Gly77Ser
c.229G>A
p.Gly77Ser
Gender Male Female
Age of onset 3m 6m
Current age 3 y 5m Deceased
Age at last clinic visit 1 y 9m 9m
Age at death N/A 9m
Growth
Poor growth + +
Poor weight gain + −
Head
circumference
50th centile Relative
macrocephaly
Ophthalmologic
Optic nerve pallor + +
Visual impairment + +
Dysmorphic features
Low set ears + −
Broad nasal bridge + −
Respiratory
Frequent infections − −
Tracheostomy − −
Gastrointestinal
Feeding difficul-
ties/aspiration
+/− +/+
Constipation − +
Nasogastric tube + −
Skeletal
Joint laxity − +
Short fourth
metacarpals
− +
Cutaneous toe
syndactyly
− +
Neurological
Development
delays
+ +
Developmental
regression
+, 6 m +, 6 m
Expressive
language
− −
Hypotonia +, truncal +, truncal
Spasticity + +
Abnormal
movements
− −
Ambulation − −
Seizure − −
Radiological
Leukodystrophy + +
MRS Elevated lactate
peak
Elevated lactate
peak
(Continues)
TABLE 1 (Continued)
Subject 1 Subject 2
T1/T2 signal
abnormalities
Increased T2 inWM
of SUF, PVWM
extending into
PLIC, PB, and SP
of CC and CP.
Diffuse T1 and T2 in
WMof FP, OC,
and both CBH
Abnormal signal
DTT, ICP, and
CWM
Abnormal T2 in CCJ
to T11 cord
Metabolic N/A
CSF
Glycine 43.0 𝜇mol/l
(1.9–10)
Glutamate 18 𝜇mol/l (0–3.9)
5-MET 46 nmol/l (72–305)
Lactate 6.69mmol/l
(1.1–2.2)
Plasma
Glycine Normal
Glutamate Normal
Other PAA Normal
Lactate 1.84mmol/l
(0.7–2.1)
Chitotriosidase 500 nmol/hr/ml
(0–150)
Palmitoyl
thioesterase
12 nmol/hr/mg
(17–139)
B-glucosidase 143 nmol/hr/mg
(163–378)
Arylsulfatase A 17 nmol/hr/mg
(22–103)
Urine
Glycine 2,393 𝜇mol/l
(92–760)
Glutamate 54 𝜇mol/l (0–32)
m, months; y, years; N/A, not applicable; MRS; functional magnetic reso-
nance spectrometry; WM, white matter; SUF, subcortical U fibers; PVWM,
periventricular white matter; PLIC, posterior limb of the internal capsule;
PB, posterior body; SP, splenium; CC, corpus callosum; CP, cerebral pedun-
cles; DTT, dorsal tegmental tracts; ICP, inferior cerebellar peduncles; CWM,
cerebellar white matter; CCJ, craniocervical junction; FP, frontoparietal;
OC, occipital; CBH, cerebellar hemispheres; CSF, cerebrospinal fluid; 5-
MET, 5-methyltetrahydrofolate; PAA, plasma amino acids.
SDHA. In addition, a marginal decrease was observed for Complex IV
subunit protein COX1 (Figure 2C).
OCRs were measured in Subject 1 fibroblasts using microscale
oxygraphy. This measurement of respiration in live cells revealed
significantly diminished oxygen consumption and ATP production in
Subject 1 (Figure 2D). Basal respiration was severely compromised
relative to control as was maximal respiration suggesting a defect in
electron flow from complexes I–IV. ATP production was reduced to
nearly half of control. In addition, spare respiratory capacity was
only 25% of control suggesting cells are likely unable to accommo-
date additional energetic demand (Figure 2D). Taken together, our
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results indicate that the ISCA2 c.229G > A; p.Gly77Ser variant in the
homozygous state severely altered the bioenergetic properties of
mitochondria.
3.4 ISCA2mutation alters mitochondrial
morphology andmtDNA copy number
To further assess the role of altered ISCA2 function in mitochon-
drial physiology, we examined the morphology and distribution of the
organelle. Mitotracker Red staining of mitochondria in Subject 1 cells
revealed an abnormal distribution and shortening of the mitochon-
drial network similar to what is observed in some mtDNA mainte-
nance disorders (Figure 3A and B). Quantitation of mtDNA copy num-
ber revealed cells retained only 25% of mtDNA content relative to
control (Figure 3C).
3.5 mtDNA depletion observed in ISCA2 subject
tissues is not caused by defects in themitochondrial
nucleoside salvage pathway
ISCA2 deficient subject fibroblasts displayed mtDNA depletion and
the mechanism for this is unknown (Figure 3C). Multiple pathways
contribute to maintenance of mtDNA including replication and nucle-
oside maintenance. ABAT (MIM#137150) encodes a dual-function
2Fe–2Smitochondrial enzyme that is responsible for the catabolism of
GABA and plays a role in the maintenance of mtDNA via its role in the
mitochondrial nucleoside salvage pathway (Besse et al., 2016; Besse
et al., 2015; Storici et al., 2004). If ISCA2 played a role in 2Fe-2S iron
cluster maturation or transfer, the mtDNA depletion could be in part
due to a reduction in function of the 2Fe–2S mitochondrial protein,
ABAT. To test whether ABAT function in this pathway is altered, we
performed nucleoside rescue assays. Subject primary cell lines were
cultured in LSM to induce G0 where DNA replication is halted, but
mitochondria continue to replicate and the mitochondrial nucleoside
salvage pathway is most heavily relied upon for replication of mtDNA.
Cells were either supplemented with dNTPs or not and measured
for mtDNA copy number. Healthy control fibroblasts displayed no
change in mtDNA copy number under either condition (Figure 3D). As
expected,ABAT deficiency subject fibroblast cultured in LSMdisplayed
a significant reduction in mtDNA copy number, but the mtDNA copy
number was rescued with addition of dNTPs to the media (Figure 3D).
ISCA2 Subject 1 fibroblasts displayed significantly reduced mtDNA
copynumber in LSM, however this effectwas unchangedwith the addi-
tion of dNTPs (Figure 3D). Our data demonstrate that the reduction
of mtDNA copy number in these patients is not due to a defect in the
2Fe–2S protein ABAT or any defect in the mitochondrial nucleoside
salvage pathway.
3.6 ISCA2 depletion results in defects in
4Fe–4S-dependent enzymes and not
2Fe–2S-dependent enzymes
Hyperglycinemia is one of the clinical features in our patient that is
less commonly observedwithmitochondrial encephalopathies. Hyper-
glycinemia often results from dysfunction of the glycine cleavage
system, the proper functioning of which requires the 4Fe–S cluster
enzyme lipoic acid synthase (LIAS)(Harmer et al., 2014). Previous stud-
ies have shown that individuals with deficiency of LIAS (Mayr et al.,
2011) or components of the Fe–S cluster machinery NFU1 (Ahting
et al., 2015; Cameron et al., 2011; Navarro-Sastre et al., 2011), BOLA3
(Ahting et al., 2015; Haack et al., 2013), IBA57 (Debray et al., 2015),
and GLRX5 (Baker et al., 2014; Wei, Weng, Lee, Hwu, & Lee, 2011)
displayed hyperglycinemia as was observed in our ISCA2 patient.
We investigated whether ISCA2 subjects may have reduced lipoy-
lation resulting from the primary defect in Fe–S cluster generation.
Immunoblotting for lipoic acid in Subject 1 fibroblasts showed dramat-
ically reduced levels of protein lipoylation in Subject 1 relative to con-
trols (Figure 4A) indicating a defect in the production of lipoic acid pre-
sumably due to faulty Fe–S cluster generation derived from mutant
ISCA2.
To further examine the role of ISCA2 in the Fe–S cluster machin-
ery and specifically in the role of mitochondrial 2Fe–2S versus 4Fe–
4S-dependent enzymes, we generated two independent ISCA2 knock-
down cell lines by stable transduction of two different ISCA2 shRNA.
Quantitation of ISCA2 mRNA in each ISCA2 knockdown cell line
showed ISCA2mRNA and protein levels reduced to below 15%of con-
trol (Figure4BandF).Weutilized these cell lines to study theactivityof
multiple enzymes that are 2Fe–2S (UQCRC2, ABAT) or 4Fe–4S depen-
dent (LIAS). Protein components of ETCcomplexes I and II contain both
2Fe–2S and4Fe–4S clusters,whereas complex III relies only on a single
2Fe–2S cluster.
Quantitation of respiratory subunits by immunoblotting in ISCA2
knockdown cell lines revealed levels of complex I subunit protein
NDUFB8 were marginally increased and complex III subunit UQCRC2
levels were unchanged. Notably, a significant decrease of complex
II subunit SDHA was observed across both ISCA2 shRNA lines
(Figure 4D). These results mirror those observed in Subject 1 fibrob-
lasts. Enzymatic activity for complexes I–IV in both ISCA2 deple-
tion lines displayed activities consistent with immunoblotting results;
the primary difference from control was significantly reduced com-
plex II activity, with mild changes in complex I and IV activity (Fig-
ure 4E). In addition, protein lipoylation was measured in each ISCA2
knockdown line. Immunoblotting of lipoic acid bound protein in each
depletion line mimicked our observations in subject fibroblasts with
severely diminished level of protein lipoylation relative to controls
(Figure 4F).
Since deficiencies in one ETC complex can influence the perfor-
mance of other ETC complexes even when a primary defect is not
present, as a control we also generated an ABAT shRNA cell line
that had ABAT mRNA and protein levels measuring ∼20% of control
(Figure 4B and C). In contrast to ISCA2 knockdown cell lines, ABAT
depletion cell lines displayed significantly reduced complex I and II pro-
tein levels andactivity alongsideelevated complex III protein andactiv-
ity (Figure 4D and E). In addition, ABAT protein and enzymatic activity
levels were directly tested to represent the 2Fe–2S class of mitochon-
drial proteins in addition toubiquinol-cytochrome c reductase complex
(UQCRC or complex III). Both the ABAT protein levels (Figure 4C) and
GABA transaminase enzymatic activity levels (Figure 4G) were normal
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F IGURE 2 ISCA2 variant alters mitochondrial bioenergetics in subject fibroblasts. A: Mitochondrial membrane potential is significantly dimin-
ished in ISCA2 deficiency subject fibroblast cell line.B: Assessment of electron transport chain complex activity of ISCA2 deficiency subject fibrob-
last revealed mildly elevated activity for complexes I and III, whereas complex II and IV were significantly reduced. C: Protein quantification by
immunoblotting shows complex I (NDUFB8) was elevated in patient cells compared with control cells, whereas complex II (SDHA) is diminished.
TOMM20 was used a mitochondrial marker and loading control. D: Microscale oxygraphy analysis of live fibroblasts demonstrated a profound
respiratory deficiency in ISCA2 subject fibroblasts (black bars), compared with healthy control fibroblast lines (white bars). Error bars for all data
indicate standard deviation. ***P< 0.001
in the ISCA2 shRNA lines consistent with the idea that ISCA2 is dis-
pensable forABAT function. Taken together theseexperimentsdemon-
strate significant deficits in the functioning of 4Fe–4S-dependent pro-
teins, LIAS, without deficiency of 2Fe–2S proteins as exemplified by
ABAT.
4 DISCUSSION
We present two new cases of ISCA2 deficiency caused by homozygous
presence of the ISCA2 c.229G > A; p.Gly77Ser variant whose clinical
presentation is consistent with the infantile-onset leukodystrophy
cases previously described. We provide additional phenotypic infor-
mation through amore comprehensive clinical description and studies
on patient cells and ISCA2 knock-down cell models. We identified a
profile ofmetabolic dysfunction that includes elevatedCSF glycine and
glutamate alongside low 5-methyltetrahydrofolate. Radiological find-
ings showed a combination of features, most notably, leukodystrophy
of the brainstemwith longitudinally extensive spinal cord involvement
and elevated lactate, and illustrate the pleiotropic effects of abnormal
ISCA2 gene function. In addition, these radiological features are similar
to findings in subjects with DARS2 mutations, though not identical
(Steenweg et al., 2011). Functional studies demonstrated that loss-
of-function of ISCA2 impairs respiration, ATP production, mitochon-
drial membrane potential, and results in shortened mitochondrial
network and diminished mtDNA copy number. Moreover, we demon-
strate that disruption of ISCA2 does not modify the function of the
2Fe–2S-dependent mitochondrial proteins ABAT and UQCRC2, but
does diminish the function of ETC complex II and protein lipoylation,
which is dependent on 4Fe–4S proteins. These discoveries support the
notion that ISCA2 likely functions in 4Fe–4S cluster assembly, which
consequently affects a diverse array of cellular processes including
proper functioning of themitochondria.
Metabolic findings revealed a signature of elevated glycine, gluta-
mate, lactate, andpyruvate inCSF,whereas all showednormal values in
plasma. Plasma or CSF glycinewas not assessed in previously reported
ISCA2 patients (Al-Hassnan et al., 2015; Lebigot et al., 2017). Subjects
with bi-allelic pathogenic variants in another gene essential for Fe–S
cluster assembly, IBA57, also show elevated glycine in CSF and plasma
(Ajit Bolar et al., 2013; Debray et al., 2015). These observations of
elevated glycine puts Fe–S cluster deficiency syndromes in the differ-
ential for a group of disorders that result in hyperglycinemia. Elevated
glycine is observed in the CSF of subjects with glycine encephalopa-
thy (CSF glycine > 80 for neonatal form; glycine > 30 for milder “atyp-
ical form”) due to recessive mutations in the glycine cleavage system
pathway genesGLDC (MIM#238300),AMT (MIM#238310), andGCSH
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F IGURE 3 ISCA2 subject fibroblast displaymitochondrial network disruption, severemtDNA depletion and lipoylation defects.A andB: Images
of control fibroblasts (A) display a ubiquitous mitochondrial distribution and networking by MitoTracker Red staining and a typical distribution
of mtDNA nucleoids by PicoGreen staining, whereas Subject 1 cells (B) display blunted mitochondrial networking with an abnormal perinuclear
distribution. C: Profound mtDNA depletion was determined in ISCA2 subject fibroblasts relative to controls. D: Quantification of mtDNA copy
number in quiescent subject fibroblast lines. ABAT subject fibroblasts show a reducedmtDNA copy number in low serummedia (LSM), butmtDNA
copy number is rescued with the addition of dNTPs. ISCA2 deficiency subject fibroblasts show reduced mtDNA copy number in LSM media, and
this remains unchanged despite the addition of dNTPs. Error bars indicate standard deviation. ***P< 0.001
(MIM#238330) (Applegarth&Toone, 2001;Nanao et al., 1994; Toone,
Applegarth, Coulter-Mackie, & James, 2000). While these gene prod-
ucts are not reliant on Fe–S clusters for proper functioning, they do
require lipoic acid, which is generated by 4Fe–4S-dependent enzymes
(Hiltunen et al., 2010). In our study, we observed a sizeable reduc-
tion in lipoylated proteins in both subject fibroblasts and ISCA2 deple-
tion models, suggesting that the 4Fe–4S-dependent enzyme LIAS is
adversely affected, and consequently lipoic acid dependent enzymes
such as those involved in the glycine cleavage system and mitochon-
drial energy metabolism. Individuals with pathogenic variants in other
Fe–S cluster proteins, NFU1, BOLA3, IBA57, andGLRX5have elevated
glycine levels suggesting that the phenotypic overlap of Fe–S defi-
ciencies with LIAS may be due to alterations in glycine cleavage (Tort,
Ferrer-Cortes, & Ribes, 2016). Another group of metabolic disorders,
such as propionic acidemias, can cause ketotic hyperglycinemia, which
produces elevated glycine in plasma and urine, however, not typically
in CSF (Gerritsen, Kaveggia, &Waisman, 1965).
Protein levels and enzymatic activity assays conducted in both
patient tissue and knockdown cell models demonstrated decreased
Complex II with intact complexes I and III. Complexes I, II and III are
structurally composed ofmultiple subunits that contain a range of Fe-S
clusters. Complex I contains a total of eight Fe/S clusters (two 2Fe–2S
and six 4Fe–4S), which are found in subunits NDUFS1, NDUFS7,
NDUFS8, NDUFV1, and NDUFV2. Complex II utilizes three Fe-S
clusters, one each of 2Fe–2S, 3Fe–4S, and 4Fe-4S, whereas complex
III carries a single 2Fe–2S cluster (Lill and Mulenhoff, 2008). In a most
simplistic model of ISCA2 playing a role in the maturation of 4Fe–4S
clusters but not 2Fe–2S clusters, it would be expected that complexes
I and II would show deficiencies and that complex III would not. A pre-
vious study using an ISCA2 knockdown model in HeLa cells, observed
diminished complex I activity assessed through a Blue Native in-gel
activity assay (Sheftel et al., 2012). This study also found decreased
complexes II, III, and IV enzymatic activity and protein levels. Previous
studies in patient fibroblasts reported decreased complex I activity
based on antibody binding (Al-Hassnan et al., 2015) and enzymatic
activity (Lebigot et al., 2017). The differences between studies may
reflect differences between cell types and/or variation due to the
various methods utilized to assess function of complexes I–IV.
Our observations of reduced complex II (SDHA) levels and activity
(SDH) indicate a role for ISCA2 in the proper functioning of SDH, in
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F IGURE 4 Characterization of ISCA2 depletion model for mitochondrial bioenergetics and lipoylation defects. A: Immunoblotting of Subject 1
fibroblasts revealed reduced ISCA2 levels. Immunoblotting for lipoic acid bound proteins found severely reduced lipoylated protein in Subject 1
fibroblasts relative to controls.B: qRT-PCR analysis of T98G glioblastoma cells expressing control non-targeting shRNA (NT shRNA), ABAT shRNA
(shABAT), and two independent ISCA2 shRNAs (shISCA2-1 and shISCA2-2). C: Immunoblotting of ABAT across each depletion line displayed a
significant reduction in protein for cells expressing ABAT shRNA, but not for cells expressing either ISCA2 shRNA.D: Significantly reduced protein
levels were observed in ABAT depleted cells for complex I (NDUFB8) and II (SDHA) proteins, but complex III (UQCRC2) protein levels were signif-
icantly elevated. Both ISCA2 depletion cells showed unchanged complex I (NDUFB8), III (UQCRC2), and IV (COXI) protein levels, but significantly
reduced complex II protein levels. TOMM20 was used as a mitochondrial marker and loading control. E: Respiratory chain complex biochemical
activity was determined in depletionmodel cells. ABAT depleted cells showed significantly reduced complex I and II levels, but elevated complex III
activity. Cells transduced with either ISCA2 shRNA displayed significantly reduced complex II activity, but relatively unchanged activity for com-
plexes I, III, and IV. Citrate synthase (CS) was unchanged across all samples. F: Cells expressing either ISCA2 shRNA displayed significantly reduced
ISCA2 protein levels and lipoic acid bound proteins.G: GABA transaminase activity was significantly reduced in cells expressing ABAT shRNA, but
not in cells expressing either ISCA2 shRNA. Error bars indicate standard deviation. ***P< 0.001
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concordance with observations that defects in 4Fe–4S cluster assem-
bly impair specific recipient enzymes (Gelling et al., 2008; Maio &
Rouault, 2015; Melber et al., 2016; Muhlenhoff et al., 2011; Sheftel
et al., 2012). Interestingly, recent studies have shown theremay be dif-
ferent mechanisms for delivery and incorporation of 4Fe–4S clusters
into SDHB, the sole Fe–S containing subunit of SDH. The study of loss-
of-function of late-acting ISCA complex member proteins Nfu1p and
Isa2p in yeast showed specific loss of SDH activity and SDHB protein
levels (Melber et al., 2016). However, the loss of function of the SDH
assembly factor SDHAF1 in mammalian cells also showed diminished
SDH activity that was dependent on early-acting ISCU complex (Maio
& Rouault, 2015). The differences between studies may reflect differ-
ences between species and/or respiratory states, and the possibility
that both complexes play a role in this sophisticated cellular process.
ISCA1/2 yeast orthologs ISA1/2 has been shown to physically inter-
act with IBA57 in S. cerevisiae and these three proteins are thought
to form a multi-protein complex that facilitates maturation of 4Fe–
4S clusters (Gelling et al., 2008). Recent work has identified two fam-
ilies with ISCA1mutations but functional work has yet to be completed
(Shukla et al., 2017). Bi-allelic variants in IBA57 have been reported in
three unrelated families to cause various clinical presentations. One
consanguineous family segregating a recessive loss-of-function vari-
ant in two siblings displayed a severeneonatal-onset encephalomyopa-
thy characterized by severe hypotonia, generalized muscle weakness,
absent primitive reflexes, microcephaly, arthrogryposis, lactic acido-
sis, hyperglycinemia and perinatal death (OMIM ID 615316)(Ajit Bolar
et al., 2013). Fibroblasts from these two siblings showedactivity of ETC
complex II was diminished and complex III normal, whereas complexes
I and IV were not measured. Similarly, in muscle of these subjects, pro-
tein levels and activity of complexes I, II, and IV were diminished and
complex IIIwas normal. A second consanguineous familywith an IBA57
splice site variantwas reportedwith a notably different clinical presen-
tation of childhood-onset slowly progressive spastic paraparesis with
optic atrophy and peripheral neuropathy referred to as Spastic Para-
plegia 74 (OMIM ID 616451) (Lossos et al., 2015). A third consan-
guineous family segregating a recessive loss-of-function variant dis-
played an intermediate phenotype relative to the other families. The
patient was asymptomatic at birth, but by 6 months displayed signs of
motor regression including progressive hypotonia and muscle weak-
ness, developmental regression and leukodystrophy resulting in death
at 17 months of age (Debray et al., 2015). Fibroblasts from this sub-
ject showed reduced complexes I and II with normal complex III activ-
ity. In the same study, a IBA57 knockdown cell model showed reduced
complex II activitywith normal complexes I and III (Debray et al., 2015).
A recent study identified reduced IBA57 protein levels in ISCA2 defi-
ciency patient fibroblasts suggesting an interaction between these
proteins and their overlapping phenotypes (Lebigot et al., 2017). The
compromise in ETC complex activity caused by IBA57 deficiency
parallels that of ISCA2 deficiency subjects with the greatest compro-
mise in oxidative phosphorylation observed in complex II, although the
precise role of ISCA2 in providing mature 4Fe–4S clusters to the ETC
complex proteins remains unresolved.
We showed ISCA2 deficiency subject's fibroblasts have an abnor-
mally short distribution of the mitochondrial network similar to what
has been observed in IBA57 deficiency fibroblasts (Ajit Bolar et al.,
2013). Analysis of mtDNA copy number identified severely depleted
levels, where Subject 1 fibroblast cells retained only 25% of mtDNA
content relative to control. This quantitative loss ofmtDNA copy num-
ber was consistent with previous reports of ISCA2 deficiency subjects
(Al-Hassnan et al., 2015). Primarymitochondrial disorders that include
depletion of mtDNA typically also show combined OXPHOS deficien-
cies involving complexes I and IV with the nuclear-encoded complex
II functionally preserved. The cellular phenotype of having mtDNA
depletion together with complex II deficiency along with hyperglycin-
emia, elevated lactate, leukodystrophy of the brainstem and complete
length of the spinal cord is a relatively unusual combination of features
that may facilitate diagnosis of ISCA2 deficiency patients in combina-
tion with genetic analyses.
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